Herceptin
Perjeta becomes first approved drug for early breast cancer
October 1, 2013Sales and Marketing FDA, Herceptin, Perjeta, Roche
Roche’s Perjeta has become the first preoperative breast cancer drug to be authorised by the FDA after it was granted …
Roche’s new Herceptin jab approved by NHS
September 25, 2013Sales and Marketing Herceptin, Kadcyla, Roche, breast cancer
EU green light for ‘new’ Herceptin
September 3, 2013Sales and Marketing EU, Herceptin, Roche, breast cancer
Roche has ticked another approval off Herceptin’s list with the news that the European Commission is allowing a new form …
GSK and Roche get EU breast cancer indication
August 15, 2013Sales and Marketing GSK, Herceptin, Roche, Tyverb, Xeloda, breast cancer
The European Commission has granted a new indication for the use of GSK’s breast cancer drug Tyverb in combination with …
FDA approves Kadcyla
February 25, 2013Herceptin, Roche, T-DM1
Roche’s new ‘smart bomb’ breast cancer drug Kadcyla has been approved by the FDA, giving it hope of replacing revenue …
Roche’s Perjeta increases survival
June 27, 2012Research and Development, Sales and Marketing EMA, FDA, Herceptin, Perjeta, Roche, breast cancer
Roche’s new drug Perjeta has scored another trial success by increasing overall survival in certain breast cancer patients. The new …
New data shows Herceptin’s ability to increase survival
April 24, 2012Research and Development, Sales and Marketing Cancer, Cochrane, Herceptin, Roche, breast
A new review of Roche’s breast cancer drug Herceptin has confirmed its ability to increase overall survival, but concerns remain …
Roche to submit Herceptin successor to regulators
April 2, 2012Research and Development, Sales and Marketing GSK, Herceptin, Roche, Xeloda
Roche has said it will submit its new breast cancer drug trastuzumab for regulatory review in the US and Europe …
Indian CMO will make Roche blockbusters
March 6, 2012Manufacturing and Production Emcure, Herceptin, India, MabThera, Pegasys, Roche
Roche has reportedly signed an agreement with Emcure Pharmaceuticals of India that will see the latter manufacturing its blockbuster drugs …
GSK pulls Tyverb extension in Europe
February 17, 2012Sales and Marketing GSK, Herceptin, Tyverb, Xeloda
GlaxoSmithKline has withdrawn its European application to extend the licence of its breast cancer pill Tyverb. The firm was seeking …
NICE cannot recommend breast cancer drugs
February 14, 2012Sales and Marketing GSK, Herceptin, NHS, NICE, Roche, Tyverb
NICE is not recommending GlaxoSmithKline’s Tyverb or Roche’s Herceptin for use in certain breast cancer patients. The watchdog said in …
FDA grants Roche’s pertuzumab priority review
February 10, 2012Sales and Marketing Herceptin, Roche, pertuzumab
The FDA has accepted Roche’s potential breast cancer treatment pertuzumab for appraisal and granted the drug priority review. The proposed …
Injectable Herceptin proves its worth
October 20, 2011Research and Development, Sales and Marketing Herceptin, Roche
An injectable version of Roche’s breast cancer drug Herceptin compares favourably to the standard intravenous infusion, according to new research. …
Roche’s Herceptin successor impresses at EMCC
September 27, 2011Research and Development Herceptin, Roche, TDM-1
Roche’s next-generation breast cancer drug T-DM1 has impressed at the European cancer congress after besting Herceptin in a new study. …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
